Study of two drugs for solid tumors with KRAS G12C mutation
Part of Cancer clinical trials.
This trial tests a combination of two experimental drugs (SY-5933 and CT-707) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cancer that has spread or cannot be removed with surgery, and it has the KRAS G12C gene change.
- You are at least 18 years old.
- You are able to get around and take care of yourself (ECOG score 0 or 1).
- Your liver, kidney, and blood cell counts are within certain limits.
- You have not been treated with a KRAS G12C inhibitor before.
- You have recovered from side effects of previous cancer treatments (except for some like hair loss).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests HS-10370, a new targeted medicine, in people with advanced solid tumors that cannot be treated with standard options. It focuses on cancers that have a specific change in the KRAS gene (KRAS G12C).
This trial tests two experimental drugs (IN10018 and RNK08954) together for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if this combination can shrink tumors when standard treatments have stopped working.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests D3S-001 (alone or with other treatments) in people with advanced solid cancers that have a KRAS G12C mutation. It’s mainly aimed at early safety and learning whether the treatment can shrink or control tumors.
This trial tests an experimental drug called PT0253 for people with advanced or metastatic cancers that have a specific genetic change called KRAS G12D. The drug may help shrink or slow the growth of these tumors, and the study will also check for side effects.
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.